🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Insulet Corporation (PODD)

NASDAQ
Currency in USD
236.67
+1.06(+0.45%)
Real-time Data
PODD Scorecard
Full Analysis
Trading at a high earnings multiple
Earnings results expected in 3 days
Fair Value
Day's Range
235.85240.78
52 wk Range
151.56243.98
Prev. Close
235.61
Open
236.02
Day's Range
235.85-240.78
52 wk Range
151.56-243.98
Volume
360,885
Average Volume (3m)
654,472
1-Year Change
44.92%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
PODD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
247.99
Upside
+4.78%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations
Show more

Insulet Corporation Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

InvestingPro Research for Insulet Corporation


Diabetes Tech Pionee
Insulet's Omnipod 5 AID system, now FDA-cleared for both Type 1 and Type 2 diabetes, opens new growth avenues in the vast, underpenetrated insulin pump market
Financial Momentum
Strong Q2 2024 results exceed expectations, with total revenue up 27% YoY to $488 million, prompting raised FY2024 guidance to 18%-21% growth
Market Expansion Potential
Explore how Omnipod 5's entry into Type 2 diabetes market, with 6 million potential new customers, could drive substantial long-term revenue growth
Analyst Perspectives
Price targets range from $200 to $236, with Canaccord Genuity maintaining a BUY rating, reflecting optimism about Insulet's market position and growth prospects
Read full SWOT analysis

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
41.9x−10.6x−0.6x
PEG Ratio
0.08−0.050.00
Price/Book
16.6x2.6x2.6x
Price / LTM Sales
8.9x3.5x3.2x
Upside (Analyst Target)
6.1%52.5%48.6%
Fair Value Upside
Unlock−0.1%7.0%Unlock

People Also Watch

385.38
WAT
-0.47%
102.33
CHRW
+0.50%
104.78
COO
-1.01%
179.83
AME
+0.78%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 236.67

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 16.62B.

What is Insulet Earnings Per Share?

The Insulet EPS is 5.65.

What Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Nov 07, 2024.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.